Skip to main content
. Author manuscript; available in PMC: 2021 Jul 8.
Published in final edited form as: Nano Lett. 2020 Jun 8;20(7):4857–4863. doi: 10.1021/acs.nanolett.0c00757

Figure 1.

Figure 1.

Hypoxia-responsive nanoparticle (HRNP) for targeting hypoxia-correlated protumorigenic gene (CDC20) in precision breast cancer therapy. (A) Significant upregulation of CDC20 mRNA was observed in breast cancer tissues compared to normal and paratumor tissues. (B) The GSEA result shows the positive correlation of CDC20 with tumor hypoxia. (C) Formulation of HRNP/siRNA and mechanism of disassembly in a hypoxic reduction environment. (D) Schematic of HRNP/siCDC20 delivery into tumor cell cytoplasm to induce G2/M arrest and cell apoptosis for effective cancer therapy.